In the majority of all patients with SM, a somatic amino acid substitution of valine for aspartic acid in the catalytic domain of KIT (p.Asp816Val or p.D816V) can be detected, which leads to a constitutive activation of the receptor. This evidence concerns the gene KIT and systemic mastocytosis.